Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
Systemic Sclerosis: Systemic Considerations and Work-Up
Description
Dr. Becca Gaffney delivered a comprehensive presentation on systemic sclerosis, highlighting its complexities as an autoimmune disease characterized by skin and internal organ fibrosis. Notably, dermatologists often identify this condition early, allowing for timely management of its systemic manifestations, which significantly affect patient outcomes. Gaffney described two main forms: limited and diffuse systemic sclerosis, each with distinct clinical features and progression patterns. She emphasized the importance of screening for extra-cutaneous involvement, including lung, gastrointestinal, renal, and cardiac complications, advocating for a multidisciplinary approach to treatment. Key treatments primarily focus on managing skin manifestations with medications like Cellcept, while addressing pulmonary hypertension and renal crises through appropriate therapeutic strategies. Gaffney underscored the need for regular monitoring and detailed work-ups to ensure swift intervention for complications that can arise in patients, further enhancing their quality of life.
View moreConclusions
- As dermatologists, we play a crucial role in the early identification of systemic sclerosis, which facilitates timely diagnosis and management of systemic manifestations.
- Systemic sclerosis is characterized by complex multi-system autoimmune changes, including vascular dysfunction and fibrosis affecting skin and internal organs.
- Early and accurate diagnosis can significantly improve morbidity and mortality through targeted therapies.
- There are defined phenotypes of systemic sclerosis—limited and diffuse—that have different clinical presentations and progression rates.
- Autoantibody profiles are vital for diagnosing, classifying, and predicting the prognosis of systemic sclerosis patients.
- Cutaneous manifestations are significant, with skin fibrosis representing a hallmark of the disease, but it's the extracutaneous features that often dictate clinical outcomes.
- Systematic screening for extracutaneous manifestations is essential in all patients suspected of having systemic sclerosis.
- A multidisciplinary team approach is critical in managing the various complications of systemic sclerosis, including lung, renal, gastrointestinal, and cardiac involvement.
- Specific treatments, such as mycophenolate mofetil, are preferred early in the disease for skin involvement, while targeted therapies are available for pulmonary hypertension.
- Regular monitoring and proactive management of potential complications, such as renal crisis and pulmonary issues, improve patient outcomes.
- Denton CP and Khanna D. Lancet 2017; 390: 1685-99.
- Takehara K, Ihn H, Sato S. Clin Exp Rheumatol 2013; 31: 151-6.
- Melvin OG, Hunt KM, Jacobson ES. JAMA Derm 2019; 7: 857-859.
- Smith L, Polsky D, Franks AG. Archives of dermatology. 2012; 148(4): 426-8.
- Barry KK, Reusch DB, Shahriari N, Lonowski S, Dedeoglu F, Vleugels RA. Pediatric Dermatology 2023.
- Roofeh, David, et al. "Treatment of systemic sclerosis-associated interstitial lung disease: lessons from clinical trials." Journal of scleroderma and related disorders (2020).
- Distler et al. 2019. The NEW ENGLAND JOURNAL of MEDICINE.